EVOK Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of -26.99% compared to Evoke Pharma, Inc.'s net margin of --. Evoke Pharma, Inc.'s return on equity of -104.51% beat Palatin Technologies's return on equity of --.

Evoke Pharma, Inc. has a consensus price target of $18.00, signalling upside risk potential of 63.64%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Evoke Pharma, Inc., analysts believe Palatin Technologies is more attractive than Evoke Pharma, Inc..

Evoke Pharma, Inc. has a beta of -0.144, which suggesting that the stock is 114.415% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Evoke Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evoke Pharma, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Evoke Pharma, Inc. quarterly revenues are $4.3M, which are larger than Palatin Technologies quarterly revenues of --. Evoke Pharma, Inc.'s net income of -$1.2M is higher than Palatin Technologies's net income of --. Notably, Evoke Pharma, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evoke Pharma, Inc. is 1.74x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -26.99% compared to Evoke Pharma, Inc.'s net margin of -45.06%. Evoke Pharma, Inc.'s return on equity of -104.51% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Evoke Pharma, Inc. has a consensus price target of $18.00, signalling upside risk potential of 63.64%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.61 which suggests that it could fall by -7.67%. Given that Evoke Pharma, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Evoke Pharma, Inc. is more attractive than Sarepta Therapeutics, Inc..

Evoke Pharma, Inc. has a beta of -0.144, which suggesting that the stock is 114.415% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.

Evoke Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evoke Pharma, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Evoke Pharma, Inc. quarterly revenues are $4.3M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Evoke Pharma, Inc.'s net income of -$1.2M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Evoke Pharma, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evoke Pharma, Inc. is 1.74x versus 0.95x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tactile Systems Technology, Inc. has a net margin of -26.99% compared to Evoke Pharma, Inc.'s net margin of 9.57%. Evoke Pharma, Inc.'s return on equity of -104.51% beat Tactile Systems Technology, Inc.'s return on equity of 8.82%.

Evoke Pharma, Inc. has a consensus price target of $18.00, signalling upside risk potential of 63.64%. On the other hand Tactile Systems Technology, Inc. has an analysts' consensus of $18.83 which suggests that it could fall by -18.28%. Given that Evoke Pharma, Inc. has higher upside potential than Tactile Systems Technology, Inc., analysts believe Evoke Pharma, Inc. is more attractive than Tactile Systems Technology, Inc..

Evoke Pharma, Inc. has a beta of -0.144, which suggesting that the stock is 114.415% less volatile than S&P 500. In comparison Tactile Systems Technology, Inc. has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.902%.

Evoke Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tactile Systems Technology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evoke Pharma, Inc. pays -- of its earnings as a dividend. Tactile Systems Technology, Inc. pays out -- of its earnings as a dividend.

Evoke Pharma, Inc. quarterly revenues are $4.3M, which are smaller than Tactile Systems Technology, Inc. quarterly revenues of $85.8M. Evoke Pharma, Inc.'s net income of -$1.2M is lower than Tactile Systems Technology, Inc.'s net income of $8.2M. Notably, Evoke Pharma, Inc.'s price-to-earnings ratio is -- while Tactile Systems Technology, Inc.'s PE ratio is 37.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evoke Pharma, Inc. is 1.74x versus 2.21x for Tactile Systems Technology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -26.99% compared to Evoke Pharma, Inc.'s net margin of --. Evoke Pharma, Inc.'s return on equity of -104.51% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Evoke Pharma, Inc. has a consensus price target of $18.00, signalling upside risk potential of 63.64%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Evoke Pharma, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Evoke Pharma, Inc..

Evoke Pharma, Inc. has a beta of -0.144, which suggesting that the stock is 114.415% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Evoke Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evoke Pharma, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Evoke Pharma, Inc. quarterly revenues are $4.3M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Evoke Pharma, Inc.'s net income of -$1.2M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Evoke Pharma, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evoke Pharma, Inc. is 1.74x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.